International circumpolar surveillance : update on the interlaboratory quality control program for Streptococcus pneumoniae, 2009 to 2020

dc.contributor.authorGolden, Alyssa R
dc.contributor.authorGriffith, Averil
dc.contributor.authorSimons, Brenna C
dc.contributor.authorReasonover, Alisa
dc.contributor.authorSlotved, Hans-Christian
dc.contributor.authorLefebvre, Brigitte
dc.contributor.authorKristinsson, Karl Gústaf
dc.contributor.authorHurteau, Donna
dc.contributor.authorTyrrell, Gregory J
dc.contributor.authorBruce, Michael G
dc.contributor.authorMartin, Irene
dc.contributor.departmentFaculty of Medicine
dc.date.accessioned2025-11-20T09:36:03Z
dc.date.available2025-11-20T09:36:03Z
dc.date.issued2024-06-04
dc.descriptionPublisher Copyright: © Crown copyright 2024.en
dc.description.abstractUNLABELLED: The International Circumpolar Surveillance (ICS) program is a population-based surveillance network for invasive bacterial diseases throughout Arctic countries and territories. The ICS quality control program for Streptococcus pneumoniae serotyping and antimicrobial susceptibility testing has been ongoing since 1999. Current participating laboratories include the Provincial Laboratory for Public Health in Edmonton, Alberta; Laboratoire de santé publique du Québec in Sainte-Anne-de-Bellevue, Québec; the Centers for Disease Control's Arctic Investigations Program in Anchorage, Alaska; the Neisseria and Streptococcus Reference Laboratory at Statens Serum Institut in Copenhagen, Denmark; the Department of Clinical Microbiology, Landspitali in Reykjavik, Iceland; and Public Health Agency of Canada's National Microbiology Laboratory in Winnipeg, Manitoba. From 2009 to 2020, 140 isolates of S. pneumoniae were distributed among the six laboratories as part of the quality control program. Overall serotype concordance was 96.9%, with 99.3% concordance to pool level. All participating laboratories had individual concordance rates >92% for serotype and >97% for pool. Overall concordance by modal minimum inhibitory concentration (MIC) for testing done by broth microdilution or Etest was 99.1%, and >98% for all antimicrobials tested. Categorical concordance was >98% by both CLSI and EUCAST criteria. For two laboratories performing disc diffusion, rates of concordance by modal MIC were >97% for most antimicrobials, except chloramphenicol (>93%) and trimethoprim/sulfamethoxazole (>88%). Data collected from 12 years of the ICS quality control program for S. pneumoniae demonstrate excellent (≥95%) overall concordance for serotype and antimicrobial susceptibility testing results across six laboratories. IMPORTANCE: Arctic populations experience several social and physical challenges that lead to the increased spread and incidence of invasive diseases. The International Circumpolar Surveillance (ICS) program was developed to monitor five invasive bacterial diseases in Arctic countries and territories. Each ICS organism has a corresponding interlaboratory quality control (QC) program for laboratory-based typing, to ensure the technical precision and accuracy of reference testing services for these regions, and identify and correct potential problems. Here, we describe the results of the ICS Streptococcus pneumoniae QC program, from 2009 to 2020. Excellent overall concordance was achieved for serotype and antimicrobial susceptibility testing results across six laboratories. Ongoing participation in these QC programs ensures the continuation of quality surveillance systems within Arctic populations that experience health disparities.en
dc.description.versionPeer revieweden
dc.format.extent326065
dc.format.extente0424523
dc.identifier.citationGolden, A R, Griffith, A, Simons, B C, Reasonover, A, Slotved, H-C, Lefebvre, B, Kristinsson, K G, Hurteau, D, Tyrrell, G J, Bruce, M G & Martin, I 2024, 'International circumpolar surveillance : update on the interlaboratory quality control program for Streptococcus pneumoniae, 2009 to 2020', Microbiology spectrum, vol. 12, no. 6, pp. e0424523. https://doi.org/10.1128/spectrum.04245-23en
dc.identifier.doi10.1128/spectrum.04245-23
dc.identifier.issn2165-0497
dc.identifier.other222995021
dc.identifier.other8c2184b6-9ac9-47a6-8f39-a22274f00263
dc.identifier.other38651880
dc.identifier.otherunpaywall: 10.1128/spectrum.04245-23
dc.identifier.other85195257096
dc.identifier.urihttps://hdl.handle.net/20.500.11815/7551
dc.language.isoen
dc.relation.ispartofseriesMicrobiology spectrum; 12(6)en
dc.relation.urlhttps://www.scopus.com/pages/publications/85195257096en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectAlaska/epidemiologyen
dc.subjectPneumococcal Infections/microbiologyen
dc.subjectStreptococcus pneumoniae/drug effectsen
dc.subjectEpidemiological Monitoringen
dc.subjectArctic Regionsen
dc.subjectHumansen
dc.subjectMicrobial Sensitivity Tests/standardsen
dc.subjectSerogroupen
dc.subjectLaboratories/standardsen
dc.subjectAnti-Bacterial Agents/pharmacologyen
dc.subjectSerotypingen
dc.subjectQuality Controlen
dc.subjectserotypingen
dc.subjectquality controlen
dc.subjectantimicrobial susceptibilityen
dc.subjectStreptococcus pneumoniaeen
dc.subjectinvasive bacterial diseaseen
dc.subjectcircumpolar surveillanceen
dc.subjectGeneral Immunology and Microbiologyen
dc.subjectMicrobiology (medical)en
dc.subjectInfectious Diseasesen
dc.subjectGeneticsen
dc.subjectPhysiologyen
dc.subjectCell Biologyen
dc.subjectEcologyen
dc.titleInternational circumpolar surveillance : update on the interlaboratory quality control program for Streptococcus pneumoniae, 2009 to 2020en
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
golden-et-al-2024-international-circumpolar-surveillance-update-on-the-interlaboratory-quality-control-program-for.pdf
Stærð:
318.42 KB
Snið:
Adobe Portable Document Format

Undirflokkur